FEDERAL AND STATE LEGISLATION TRACKING
Federal Legislation & Government Insights Tracking and Coverage
Gain access to reports and strategic insights written by our team of legal analysts, clinical pharmacists, and senior researchers covering legislation and government-related lawsuits that may have an impact on drug pricing, patient access, drug reimbursement, and intellectual property covering drug products.
Focused on high-impact bills, rules, regulations, executive orders, and government-related lawsuits, our Legislation & Government Insights will help you understand their potential effects on the marketplace and healthcare stakeholders.
In addition to comprehensive reports and real-time email updates following legislation moving through the House of Representatives or Senate and being challenged in court, our High-Impact Legislation & Government Insights Tracker allows you to easily monitor statuses, outcomes, and important details of each ongoing situation.
State Legislation & Government Insights Tracking and Coverage
Track current and proposed state legislation impacting payer coverage, drug pricing, utilization management, pharmacy benefit managers, pharmacy practices, and more with access to state-by-state topic coverage, data visualizations, source information, and consults with our expert team.
Explore Recent Reports
May 2026
Most-Favored-Nation Drug Pricing Update: Regeneron Agreement and Observations on New Drug Pricing
IPD Analytics has released a new report, “Most-Favored-Nation Drug Pricing Update: Regeneron Agreement and Observations on New Drug Pricing.” On April 23, 2026, Regeneron reached a “most-favored-nation” (MFN) pricing agreement with the Trump administration, as the last among 17 manufacturers that the White House says represent 86% of the branded drug market.
February 2026
Most-Favored Nation Drug Pricing: An Update
IPD Analytics has released a new report that analyzes the recent developments in the Trump administration’s most-favored-nation (MFN) drug pricing initiative. Introduced through an executive order in May 2025, the MFN policy has advanced rapidly.